267 related articles for article (PubMed ID: 26189932)
21. Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study.
Karras D; Stoykov I; Lems WF; Langdahl BL; Ljunggren Ö; Barrett A; Walsh JB; Fahrleitner-Pammer A; Rajzbaum G; Jakob F; Marin F
J Rheumatol; 2012 Mar; 39(3):600-9. PubMed ID: 22247365
[TBL] [Abstract][Full Text] [Related]
22. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
23. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
Saag KG; Zanchetta JR; Devogelaer JP; Adler RA; Eastell R; See K; Krege JH; Krohn K; Warner MR
Arthritis Rheum; 2009 Nov; 60(11):3346-55. PubMed ID: 19877063
[TBL] [Abstract][Full Text] [Related]
24. Analysis of daily teriparatide treatment for osteoporosis in men.
Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Kono T; Sudo A
Osteoporos Int; 2015 Apr; 26(4):1303-9. PubMed ID: 25567777
[TBL] [Abstract][Full Text] [Related]
25. A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis.
Hagino H; Narita R; Yokoyama Y; Watanabe M; Tomomitsu M
Osteoporos Int; 2019 Oct; 30(10):2027-2037. PubMed ID: 31243480
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of teriparatide in bisphosphonate-pretreated and treatment-naive patients with osteoporosis at high risk of fracture: Post hoc analysis of a prospective observational study.
Yoshiki F; Nishikawa A; Taketsuna M; Kajimoto K; Enomoto H
J Orthop Sci; 2017 Mar; 22(2):330-338. PubMed ID: 28038880
[TBL] [Abstract][Full Text] [Related]
27. Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo® Observational Study (ExFOS).
Napoli N; Langdahl BL; Ljunggren Ö; Lespessailles E; Kapetanos G; Kocjan T; Nikolic T; Eiken P; Petto H; Moll T; Lindh E; Marin F
Calcif Tissue Int; 2018 Oct; 103(4):359-371. PubMed ID: 29909449
[TBL] [Abstract][Full Text] [Related]
28. Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study.
Cohen A; Stein EM; Recker RR; Lappe JM; Dempster DW; Zhou H; Cremers S; McMahon DJ; Nickolas TL; Müller R; Zwahlen A; Young P; Stubby J; Shane E
J Clin Endocrinol Metab; 2013 May; 98(5):1971-81. PubMed ID: 23543660
[TBL] [Abstract][Full Text] [Related]
29. Skeletal response to treatment with teriparatide (TPD) after bisphosphonate in post-menopausal women with osteoporosis and a high prevalence of secondary risk factors in real-life setting of a metabolic bone clinic; effect of age and vitamin D status.
Mok J; Brown C; Moore AEB; Min SS; Hampson G
Endocr Res; 2018 Aug; 43(3):195-202. PubMed ID: 29652557
[TBL] [Abstract][Full Text] [Related]
30. 24-Month Open-Label Teriparatide Once-Weekly Efficacy Research Trial Examining Bone Mineral Density in Subjects with Primary Osteoporosis and High Fracture Risk.
Sugimoto T; Shiraki M; Fukunaga M; Hagino H; Sone T; Nakano T; Kishimoto H; Ito M; Yoshikawa H; Kishida M; Irie C; Nakamura T
Adv Ther; 2017 Jul; 34(7):1727-1740. PubMed ID: 28631217
[TBL] [Abstract][Full Text] [Related]
31. Effect of a patient-support program on once-daily teriparatide adherence and persistence in the Japan Fracture Observational Study (JFOS).
Sato M; Tsujimoto M; Kajimoto K; Uetake H; Shimoda H; Fujiwara S
Arch Osteoporos; 2018 Jul; 13(1):74. PubMed ID: 29978364
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of Teriparatide in women over 75 years of age with severe osteoporosis: 36-month results from the European Forsteo Observational Study (EFOS).
Walsh JB; Lems WF; Karras D; Langdahl BL; Ljunggren O; Fahrleitner-Pammer A; Barrett A; Rajzbaum G; Jakob F; Marin F
Calcif Tissue Int; 2012 May; 90(5):373-83. PubMed ID: 22466444
[TBL] [Abstract][Full Text] [Related]
33. Conducting an observational study during an economic crisis: analysis of the treatment and follow-up phase of Greek patients participating in the ExFOS study.
Aloumanis K; Kapetanos G; Alexandridis T; Drossinos V; Papaioannou N;
Hormones (Athens); 2018 Dec; 17(4):531-540. PubMed ID: 30430458
[TBL] [Abstract][Full Text] [Related]
34. Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs.
Iwamoto N; Okamoto M; Tsuji S; Endo Y; Takatani A; Shimizu T; Umeda M; Fukui S; Sumiyoshi R; Igawa T; Koga T; Kawashiri SY; Aramaki T; Ichinose K; Tamai M; Nakamura H; Origuchi T; Eguchi K; Ueki Y; Kawakami A
J Bone Miner Metab; 2019 May; 37(3):554-562. PubMed ID: 30187273
[TBL] [Abstract][Full Text] [Related]
35. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
Saag KG; Shane E; Boonen S; Marín F; Donley DW; Taylor KA; Dalsky GP; Marcus R
N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959
[TBL] [Abstract][Full Text] [Related]
36. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.
Nakamura T; Sugimoto T; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Yoshikawa H; Nishizawa Y; Fujita T; Shiraki M
J Clin Endocrinol Metab; 2012 Sep; 97(9):3097-106. PubMed ID: 22723322
[TBL] [Abstract][Full Text] [Related]
37. Back pain in patients with severe osteoporosis on teriparatide or antiresorptives: a prospective observational study in a multiethnic population.
Songpatanasilp T; Mumtaz M; Chhabra H; Yu M; Sorsaburu S
Singapore Med J; 2014 Sep; 55(9):493-501. PubMed ID: 25273935
[TBL] [Abstract][Full Text] [Related]
38. Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
Sugimoto T; Shiraki M; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Kuroda T; Nakamura T
Curr Med Res Opin; 2013 Mar; 29(3):195-203. PubMed ID: 23259702
[TBL] [Abstract][Full Text] [Related]
39. Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS).
Fahrleitner-Pammer A; Langdahl BL; Marin F; Jakob F; Karras D; Barrett A; Ljunggren Ö; Walsh JB; Rajzbaum G; Barker C; Lems WF
Osteoporos Int; 2011 Oct; 22(10):2709-19. PubMed ID: 21113576
[TBL] [Abstract][Full Text] [Related]
40. Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study.
Sugimoto T; Shiraki M; Fukunaga M; Kishimoto H; Hagino H; Sone T; Nakano T; Ito M; Yoshikawa H; Minamida T; Tsuruya Y; Nakamura T
Osteoporos Int; 2019 Nov; 30(11):2321-2331. PubMed ID: 31392401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]